Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-03-02
2010-06-29
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07745399
ABSTRACT:
The present invention relates to an immunostimulatory peptide derived from an Hsp70 protein and peptides comprising said immunostimulatory peptide. Furthermore the present invention pertains to polynucleotides encoding said peptide, vectors comprising said polynucleotides, fusion (poly)peptides comprising said peptide and compositions comprising said peptide. In addition the present invention relates to the use of said peptide, polynucleotide, vector or fusion (poly)peptide, for the preparation of pharmaceutical compositions for the treatment of diseases and for the stimulation of natural killer cell (NK cell) activity.
REFERENCES:
patent: WO 1997/28688 (1997-08-01), None
patent: 9949881 (1999-10-01), None
patent: 003113 (2000-06-01), None
Gabriele Multhoff, Claus Botzler and Rolf Issels; The Role of Heat Shock Proteins in the Stimulation of an Immune Response; Biol. Chem., vol. 379, pp. 295-300, Mar. 1998.
Freshney, Culture of Animal Cells, A Manual of Basic Technique 1983; 4, Alan R. Liss, Inc.
Dermer G., “Another Anniversary fo the War on Cancer,” Bio/Technology (1994) 12:320.
Bellone M., et al, “Cancer immunotherapy: synthetic and natural peptides in the balance,” Immunology Today, (1999) 20(10): 457-461.
Gura T., “Systems for Identifying new Drugs are Often Faulty,” Science (1997) 278: 1041-1042.
Joshi et al, “Analysis of Immune Responses against T-and B-Cell Epitopes from Plasmodium falciparum Liver-Stage Antigen 1 in Rodent Malaria Models and Malaria-Exposed Human Subjects in India,” Infection and Immunity 2000: 141-150, American Society for Microbiology (2000).
Alexander et al, “Mimicking the alloantigenicity of proteins with chemically synthesized peptides differing in single amino acids,” Nature (1983) 306: 697-699.
1st Office Action for corresponding European patent application 01 980 380.8 (regional phase based on PCT/ EP01/10593), dated Jun. 6, 2006.
2nd Office Action for corresponding European patent application 01 980 380.8 (regional phase based on PCT/ EP01/10593), dated Feb. 22, 2008.
Supplementary data sheets 1-5 submitted with letter of Jul. 14, 2007 in corresponding European patent application 01 980 380.8, cited as reference D4 in 2nd Office Action.
Office Action for U.S. Appl. No. 10/380,408 (US national phase of PCT/EP01/10593), of which the present application claims the benefit of priority, dated Jul. 26, 2006.
Office Action for U.S. Appl. No. 10/380,408 (US national phase of PCT/EP01/10593), of which the present application claims the benefit of priority, dated Dec. 19, 2006.
Office Action for U.S. Appl. No. 10/380,408 (US national phase of PCT/EP01/10593), of which the present application claims the benefit of priority, dated Jun. 22, 2007.
Office Action for U.S. Appl. No. 10/380,408 (US national phase of PCT/EP01/10593), of which the present application claims the benefit of priority, dated Jan. 2, 2008.
Office Action for US Non-Provisional Application No. 10/380,408 (US national phase of PCT/EP01/10593), of which the present application claims the benefit of priority, dated Jul. 24, 2008.
Casimir Jones S.C.
multimmune GmbH
Yaen Christopher H
LandOfFree
Hsp70 peptide stimulating natural killer (NK) cell activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hsp70 peptide stimulating natural killer (NK) cell activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hsp70 peptide stimulating natural killer (NK) cell activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244527